Clinical trial
SPECT Study With SB-773812 In Schizophrenic Patients
NCT00269035 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00269035 |
|---|---|
| Title | SPECT Study With SB-773812 In Schizophrenic Patients |
| Official title | A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | SB773812, Risperidone |
| Enrollment | 95 |
| Start date | Jun 21, 2005 |
| Primary completion | May 26, 2007 |
| Completion | May 26, 2007 |
| First posted | Dec 23, 2005 |
| Last update posted | Aug 17, 2017 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: